Arax Advisory Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.5M | Buy |
811,104
+731,248
| +916% | +$19.1M | 0.13% | 166 |
|
|
2026
Q1 | $2.24M | Buy |
79,856
+5,834
| +8% | +$155K | 0.06% | 248 |
|
|
2025
Q4 | $1.84M | Sell |
74,022
-82,973
| -53% | -$2.09M | 0.05% | 250 |
|
|
2025
Q3 | $4M | Buy |
156,995
+125,899
| +405% | +$3.11M | 0.06% | 278 |
|
|
2025
Q2 | $860K | Buy |
31,096
+9,859
| +46% | +$230K | 0.04% | 274 |
|
|
2025
Q1 | $538K | Sell |
21,237
-17,740
| -46% | -$464K | 0.03% | 302 |
|
|
2024
Q4 | $1.03M | Buy |
38,977
+29,229
| +300% | +$793K | 0.07% | 170 |
|
|
2024
Q3 | $282K | Buy |
9,748
+509
| +6% | +$14.8K | 0.03% | 285 |
|
|
2024
Q2 | $259K | Buy |
9,239
+787
| +9% | +$21.7K | 0.03% | 290 |
|
|
2024
Q1 | $235K | Buy |
8,452
+128
| +2% | +$3.55K | 0.02% | 277 |
|
|
2023
Q4 | $240K | Sell |
8,324
-1,579
| -16% | -$47.7K | 0.03% | 265 |
|
|
2023
Q3 | $328K | Sell |
9,903
-898
| -8% | -$31.8K | 0.04% | 198 |
|
|
2023
Q2 | $396K | Sell |
10,801
-4,010
| -27% | -$156K | 0.05% | 152 |
|
|
2023
Q1 | $604K | Sell |
14,811
-168
| -1% | -$7.26K | 0.08% | 103 |
|
|
2022
Q4 | $768K | Buy |
14,979
+121
| +0.8% | +$5.8K | 0.11% | 85 |
|
|
2022
Q3 | $650K | Buy |
14,858
+1,240
| +9% | +$60.3K | 0.1% | 84 |
|
|
2022
Q2 | $714K | Buy |
13,618
+218
| +2% | +$11.1K | 0.11% | 85 |
|
|
2022
Q1 | $694K | Buy |
13,400
+214
| +2% | +$11.1K | 0.09% | 85 |
|
|
2021
Q4 | $779K | Buy |
13,186
+5,835
| +79% | +$289K | 0.1% | 83 |
|
|
2021
Q3 | $316K | Buy |
7,351
+505
| +7% | +$22.4K | 0.04% | 170 |
|
|
2021
Q2 | $268K | Buy |
+6,846
| New | +$266K | 0.04% | 203 |
|
|
2020
Q4 | $383K | Sell |
10,406
-502
| -5% | -$18.4K | 0.06% | 112 |
|
|
2020
Q3 | $380K | Buy |
10,908
+3,248
| +42% | +$114K | 0.06% | 103 |
|
|
2020
Q2 | $238K | Sell |
7,660
-3,396
| -31% | -$115K | 0.04% | 153 |
|
|
2020
Q1 | $342K | Sell |
11,056
-10,783
| -49% | -$367K | 0.08% | 92 |
|
|
2019
Q4 | $812K | Sell |
21,839
-39
| -0.2% | -$1.39K | 0.23% | 50 |
|
|
2019
Q3 | $746K | Buy |
21,878
+49
| +0.2% | +$1.78K | 0.23% | 52 |
|
|
2019
Q2 | $897K | Buy |
+21,829
| New | +$867K | 0.3% | 40 |
|
|
2018
Q4 | $941K | Buy |
22,722
+5,318
| +31% | +$221K | 0.37% | 34 |
|
|
2018
Q3 | $728K | Sell |
17,404
-1,711
| -9% | -$65.9K | 0.29% | 41 |
|
|
2018
Q2 | $657K | Buy |
19,115
+1,861
| +11% | +$63.6K | 0.29% | 36 |
|
|
2018
Q1 | $580K | Sell |
17,254
-287
| -2% | -$9.87K | 0.3% | 34 |
|
|
2017
Q4 | $602K | Buy |
17,541
+156
| +0.9% | +$5.32K | 0.26% | 33 |
|
|
2017
Q3 | $588K | Buy |
17,385
+3,070
| +21% | +$98.7K | 0.28% | 31 |
|
|
2017
Q2 | $457K | Buy |
14,315
+793
| +6% | +$25K | 0.22% | 38 |
|
|
2017
Q1 | $438K | Buy |
13,522
+871
| +7% | +$27.5K | 0.21% | 32 |
|
|
2016
Q4 | $390K | Buy |
+12,651
| New | +$386K | 0.2% | 32 |
|
Other funds holding PFE
Arax Advisory Partners's PFE Position: Q2 2026 in Review
Arax Advisory Partners increased its Pfizer (PFE) stake by 916% in Q2 2026, buying an estimated $19.1M and bringing the position to 811,104 shares worth $19.5M. The position accounts for 0.13% of the portfolio, ranked #166.
Arax Advisory Partners first reported a position in PFE in Q4 2016 and has held it in 37 quarters since. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Arax Advisory Partners held 811,104 shares of Pfizer worth $19.5M as of Q2 2026.
- Arax Advisory Partners bought 731,248 Pfizer shares in Q2 2026, an estimated $19.1M.
- Pfizer made up 0.13% of Arax Advisory Partners's portfolio in Q2 2026, its #166 holding.
- Arax Advisory Partners first reported a position in Pfizer in Q4 2016 and has held it in 37 quarters since.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.